Search results for " Infectious Diseases"

showing 10 items of 138 documents

Complex Regulatory Networks Governing Production of the Glycopeptide A40926

2018

Glycopeptides (GPAs) are an important class of antibiotics, with vancomycin and teicoplanin being used in the last 40 years as drugs of last resort to treat infections caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus. A few new GPAs have since reached the market. One of them is dalbavancin, a derivative of A40926 produced by the actinomycete Nonomuraea sp. ATCC 39727, recently classified as N. gerenzanensis. This review summarizes what we currently know on the multilevel regulatory processes governing production of the glycopeptide A40926 and the different approaches used to increase antibiotic yields. Some nutrients, e.g., valine, l-glutamine and mal…

0301 basic medicineMicrobiology (medical)medicine.drug_class030106 microbiologyAntibioticsInfectious DiseaseReviewGlycopeptide antibioticBiologyLuxR solomedicine.disease_causeBiochemistryMicrobiologyMicrobiology03 medical and health sciencesStrRValinemedicinePharmacology (medical)General Pharmacology Toxicology and PharmaceuticsA40926Regulatory geneRegulator geneTeicoplaninlcsh:RM1-950DalbavancinLALA40926; Dalbavancin; Dbv cluster; Glycopeptide antibiotics; LAL; LuxR solo; Regulatory genes; StrR; Microbiology; Biochemistry; Pharmacology Toxicology and Pharmaceutics (all); Microbiology (medical); Infectious Diseases; Pharmacology (medical)regulatory genesGlycopeptidelcsh:Therapeutics. PharmacologyInfectious DiseasesDalbavancinStaphylococcus aureusPharmacology Toxicology and Pharmaceutics (all)Dbv clusterVancomycinglycopeptide antibioticsmedicine.drugAntibiotics
researchProduct

Editorial: Understanding Gamma Delta T Cell Multifunctionality - Towards Immunotherapeutic Applications.

2020

Introduction: gd T cells have been characterized by the expression of a gd T cell receptor (TCR).When the gd TCR and the corresponding ab TCR were first discovered it was assumed that the corresponding cell types were likely to be functionally very similar. However, some 30 years later, we have realized that they are not. Unlike ab T cells, gd T cells (i) sense target antigens independent of MHC molecules; (ii) display NK-cell like innate reactivities, including killing of infected cells as well as microbes; (iii) are able to take up large particulates, including bacteria, and (iv) can act as professional antigen presenting cells. The “stress sensing” abilities of gd T cells have led to a g…

lcsh:Immunologic diseases. Allergy0301 basic medicineCell typeT cellImmunologygd T cells gd T cell receptor antigen recognition killing mechanisms infectious diseases tumor immunology.Major histocompatibility complexLigandsinfectious diseasesCommunicable DiseasesImmunotherapy Adoptiveγδ T cellsγδ T cell receptor03 medical and health sciences0302 clinical medicineAntineoplastic Agents ImmunologicalLymphocytes Tumor-InfiltratingAntigenAnti-Infective AgentsT-Lymphocyte SubsetsNeoplasmsmedicineImmunology and AllergyAnimalsHumanstumor immunologyGamma delta T cellAntigen-presenting cellSettore MED/04 - Patologia GeneralebiologyT-cell receptorReceptors Antigen T-Cell gamma-deltakilling mechanismsAcquired immune systemCell biologyantigen recognition030104 developmental biologymedicine.anatomical_structurePhenotypeEditorialbiology.proteinlcsh:RC581-607030215 immunologySignal TransductionFrontiers in immunology
researchProduct

Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease in…

2011

Abstract Background Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce. Methods Subjects with virological success on first-PI-regimens who switched to NNRTI therapy (NNRTI group) or to nucleoside reverse transcriptase (NRTI)-only (NRTI group) were studied. The effect of the switch on the ongoing CD4+ trend was assessed by two-phase linear regression (TPLR), allowing us to evaluate whether a change in the CD4+ trend (hinge) occurred and the time of its occurrence. Furthermore, we described the evolution of the frequencies in CD4-count classes across four relevant time-points (baseline, before and immediately after…

AdultCD4-Positive T-LymphocytesMalemedicine.medical_treatmentProtease InhibitorHuman immunodeficiency virus (HIV)CD4+ T-cellHIV InfectionsBiologymedicine.disease_causeSettore MED/17 - MALATTIE INFETTIVENucleoside Reverse Transcriptase InhibitorTimelcsh:Infectious and parasitic diseasesZidovudineRetrospective Studieimmune system diseasesAntiretroviral Therapy Highly ActivemedicineHumansProtease inhibitor (pharmacology)HIV InfectionProtease Inhibitorslcsh:RC109-216Retrospective StudiesHIV; CD4+ T-cellProteaseCd4 t cellDrug SubstitutionBackground dataHIVvirus diseasesMiddle AgedVirologyHIV; AIDS; CD4; NRTIReverse Transcriptase InhibitorCD4 Lymphocyte CountInfectious DiseasesCD4-Positive T-LymphocyteReverse Transcriptase InhibitorsRitonavirFemaleAdult; Antiretroviral Therapy Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; HIV Infections; Humans; Male; Middle Aged; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Time; Drug Substitution; Infectious Diseasesmedicine.drugHumanResearch Article
researchProduct

Cost-Effectiveness Analysis of Different Testing Strategies that Use Antibody Levels to Detect Chronic Hepatitis C in Blood Donors.

2016

Aim. We conducted a cost-effectiveness analysis of seven hepatitis C virus (HCV) testing strategies in blood donors. Methods. Three of the seven strategies were based on HCV diagnosis and reporting guidelines in Mexico and four were from previous and current recommendations outlined by the CDC. The strategies that were evaluated determine antibody levels according to the signal-to-cut-off (S/CO) ratio and use reflex Immunoblot (IMB) or HCV RNA tests to confirm true positive (TP) cases of chronic HCV infection. Costs were calculated from the perspective of the Mexican Institute of Social Security (IMSS). A decision tree model was developed to estimate the expected number of true positive cas…

RNA virusesDecision AnalysisPhysiologyEconomicsCost-Benefit AnalysisSocial Scienceslcsh:MedicineBlood DonorsHepacivirusmedicine.disease_causeBiochemistryHepatitis0302 clinical medicineImmune Physiology030212 general & internal medicineChroniclcsh:SciencePathology and laboratory medicinehealth care economics and organizationsMultidisciplinaryImmune System ProteinsCost–benefit analysisHepatitis C virusLiver DiseaseCost-effectiveness analysisMedical microbiologyHepatitis CHCV AntibodyInfectious DiseasesVirusesEngineering and TechnologyBlood Banks030211 gastroenterology & hepatologyPathogensInfectionManagement EngineeringResearch Articlemedicine.medical_specialtyGeneral Science & TechnologyHepatitis C virusImmunologyCost-Effectiveness AnalysisImmunoblottingChronic Liver Disease and CirrhosisMolecular Probe TechniquesAntibody levelResearch and Analysis MethodsMicrobiologyAntibodies03 medical and health sciencesChronic hepatitisHepatitis - CClinical ResearchInternal medicineparasitic diseasesmedicineHumansImmunoassaysMolecular Biology TechniquesSensitivity analysesMolecular BiologyMedicine and health sciencesBiology and life sciencesFlavivirusesbusiness.industryDecision Treeslcsh:RHepatitis C antibodyOrganismsViral pathogensProteinsHepatitis C ChronicHepatitis C AntibodiesHepatitis virusesEconomic AnalysisMicrobial pathogensHealth CareEmerging Infectious DiseasesCost Effectiveness ResearchHealth Care FacilitiesImmunologyImmunologic Techniqueslcsh:QbusinessDigestive Diseases
researchProduct

Real life experiences in HCV management in 2018

2019

Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access to antiviral therapy and treatment optimiza…

0301 basic medicinehepatitis C virusSofosbuvirSustained Virologic ResponseAntiviral therapyAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Microbiology; Microbiology (medical); Infectious Diseases; Virologymedicine.disease_causeChronic liver diseaseHealth Services Accessibility0302 clinical medicinedirect acting antiviralshepatitis C viruMass Screening030212 general & internal medicineChronicComputingMilieux_MISCELLANEOUSHepatitis CHepatitis BHepatitis CPibrentasvirAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C Chronic; Humans; Italy; Mass Screening; Sustained Virologic ResponseInfectious DiseasesItalyHCVDisease ProgressionAntiviral therapy; chronic liver disease; DAAs; HCV; hepatitis C virus; Antiviral Agents; Disease Progression; Health Services Accessibility; Hepatitis C; Chronic; Humans; Italy; Mass Screening; Sustained Virologic Responsemedicine.drugHumanMicrobiology (medical)Settore MED/17 - Malattie InfettiveHepatitis C virus030106 microbiologyInfectious DiseaseAntiviral AgentsMicrobiology03 medical and health sciencesVirologymedicineHumansAntiviral therapy; DAAs; HCV; chronic liver disease; direct acting antivirals; hepatitis C virusMass screeningDAAHepatitis B virusAntiviral Agentbusiness.industrychronic liver diseaseDAAsHepatitis C Chronicmedicine.diseaseVirologybusiness
researchProduct

Epidemiology of intensive care unit-acquired sepsis in Italy: Results of the SPIN-UTI network

2018

Background. Sepsis is the major cause of mortality from any infectious disease worldwide. Sepsis may be the result of a healthcare associated infection (HAI): the most frequent adverse events during care delivery especially in Intensive Care Units (ICUs). The main aim of the present study was to describe the epidemiology of ICU-acquired sepsis and related outcomes among patients enrolled in the framework of the Italian Nosocomial Infections Surveillance in ICUs - SPIN-UTI project. Study design. Prospective multicenter study. Methods. The SPIN-UTI network adopted the European protocols for patient-based HAI surveillance. Results. During the five editions of the SPIN-UTI project, from 2008 to…

Sleep Initiation and Maintenance DisorderMaleTime FactorsHealthcare-associated infections; Mortality; Sepsis; Surveillance; Public Health Environmental and Occupational Health; Infectious DiseasesDiet MediterraneanCoffeeHealth StatuHealthcare-associated infections; Mortality Parole chiave: Infezioni correlate all'assistenza; Mortalità; Sepsi; Sepsis; Sorveglianza; Surveillance; Public Health Environmental and Occupational Health; Infectious DiseasesAcademic PerformancePrevalenceSurveys and QuestionnaireHospital MortalityProspective StudiesCross InfectionSurveillanceIncidenceSmokingTryptophanShockMiddle AgedShock SepticMortalitàIntensive Care UnitsInfectious DiseasesItalyPopulation SurveillanceFemalePublic HealthHumanAdultEmploymentAlcohol DrinkingSepsiIntensive Care UnitHealthcare-associated infectionsRegression AnalysiYoung AdultAge DistributionSepsisLearningHumansHealthcare-associated infectionMortalityExerciseLife StyleSettore MED/42 - IGIENE GENERALE E APPLICATAAgedCross-Sectional StudieHealthcare-associated infections; Mortality; Sepsis; SurveillanceSepticEnvironmental and Occupational HealthBody WeightLength of StayBody HeightProspective StudieSorveglianzaQuality of LifeStudents NursingMortality Parole chiave: Infezioni correlate all'assistenza
researchProduct

Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genot…

2019

Nucleos(t)ide analogues (NAs) and peginterferon have complementary effects in chronic hepatitis B, but it is unclear whether combination therapy improves responses in genotype D-infected patients. We conducted an open-label study of peginterferon alfa-2a 180 μg/week added to ongoing NA therapy in hepatitis B e antigen (HBeAg)-negative, genotype D-infected patients with HBV DNA <20 IU/mL. The primary endpoint was proportion of patients with ≥50% decline in serum HBsAg by the end of the 48-week add-on phase. Seventy patients received treatment, 11 were withdrawn at week 24 for no decrease in HBsAg, and 14 withdrew for other reasons. Response rate (per-protocol population) was 67.4% (29/43) at…

MaleHBsAgGastroenterologyPolyethylene Glycolschronic hepatitis B; HBeAg-negative; nucleos(t)ide analogues; peginterferon; treatment; Hepatology; Infectious Diseases; Virology0302 clinical medicineInterferonGenotypeHBVHepatitis B e Antigenspeginterferonchronic hepatitis b; hbeag-negative; nucleos(t)ide analogues; peginterferon; treatment; adult; antiviral agents; drug administration schedule; drug therapy combination; female; genotype; hepatitis b e antigens; hepatitis b virus; hepatitis b chronic; humans; interferon-alpha; male; middle aged; nucleosides; polyethylene glycols; recombinant proteins; treatment outcomeeducation.field_of_studytreatmentnucleos(t)ide analoguesvirus diseasesNucleosidesMiddle AgedRecombinant ProteinsTreatment OutcomeInfectious Diseasesnucleos(t)ide analogueHBeAg030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyPeginterferon alfa-2amedicine.drugAdultHepatitis B virusmedicine.medical_specialtyGenotypeCombination therapyPopulationHBeAg-negativeInfectious DiseaseHBeAg-negative; chronic hepatitis B; nucleos(t)ide analogues; peginterferon; treatmentchronic hepatitis B; HBeAg-negative; nucleos(t)ide analogues; peginterferon; treatmentAntiviral AgentsDrug Administration Schedule03 medical and health sciencesHepatitis B ChronicInternal medicineVirologymedicineHumanschronic hepatitis BeducationHepatologybusiness.industryInterferon-alphaConfidence intervalbusiness
researchProduct

Counseling intervention to improve quality of life in patients with pre-existing acute myocardial infarction (AMI) or chronic obstructive pulmonary d…

2018

In the light of diagnostic and therapeutic advances, patients with a previous myocardial infarction or with a diagnosis of chronic obstructive pulmonary disease are vulnerable and need continuous monitoring over time. These pathological frameworks have a strong impact on the economy and on the status of the population and require effective and low-cost solutions.The objective of this clinical trial is to evaluate the efficacy in the short term of a telephone counseling intervention to modify the lifestyles of these two patient populations.In May 2015, all the patients included in the study underwent a questionnaire to evaluate their eating and smoking habits and their quality of life. After…

CounselingQuality of lifeChronic Obstructiveenvironmental and occupational healthChronic obstructive pulmonary diseaseTertiary preventionpublic healthMyocardial InfarctionPilot Projectsacute myocardial infarction; chronic disease; chronic obstructive pulmonary disease; counseling; nutrition; quality of life; smoke; tertiary prevention; public health environmental and occupational health; infectious diseasesAcute myocardial infarctioninfectious diseasesAcute myocardial infarction; Chronic disease; Chronic obstructive pulmonary disease; Counseling; Nutrition; Quality of life; Smoke; Tertiary preventionChronic diseasePulmonary DiseasePulmonary Disease Chronic ObstructiveSmokeAcute myocardial infarction; Chronic disease; Chronic obstructive pulmonary disease; Counseling; Nutrition; Quality of life; Smoke; Tertiary prevention; Humans; Myocardial Infarction; Pilot Projects; Pulmonary Disease Chronic Obstructive; Quality of Life; CounselingSettore MED/42HumansOriginal ArticlePilot ProjectNutritionHuman
researchProduct

Global Functional Analyses of Cellular Responses to Pore-Forming Toxins

2011

Here we present the first global functional analysis of cellular responses to pore-forming toxins (PFTs). PFTs are uniquely important bacterial virulence factors, comprising the single largest class of bacterial protein toxins and being important for the pathogenesis in humans of many Gram positive and Gram negative bacteria. Their mode of action is deceptively simple, poking holes in the plasma membrane of cells. The scattered studies to date of PFT-host cell interactions indicate a handful of genes are involved in cellular defenses to PFTs. How many genes are involved in cellular defenses against PFTs and how cellular defenses are coordinated are unknown. To address these questions, we pe…

MAPK/ERK pathwayTranscription GeneticImmunology/Innate ImmunityMessengerInteractomeInfectious Diseases/Bacterial InfectionsRNA interference2.1 Biological and endogenous factorsAetiologyBiology (General)Genes HelminthCaenorhabditis elegansOligonucleotide Array Sequence AnalysisGenetics0303 health sciencesGenomebiologyReverse Transcriptase Polymerase Chain ReactionGenetics and Genomics/Functional Genomics030302 biochemistry & molecular biologyrespiratory systemCell biologyInfectious DiseasesMedical MicrobiologyRNA InterferenceSignal transductionDNA microarrayTranscriptionBiotechnologyResearch ArticleSignal TransductionPore Forming Cytotoxic ProteinsQH301-705.5Virulence FactorsMAP Kinase Signaling System1.1 Normal biological development and functioningBacterial ToxinsImmunologyMicrobiologyDNA-binding proteinCell Line03 medical and health sciencesBacterial ProteinsGeneticUnderpinning researchVirologyEscherichia coliHelminthGeneticsAnimalsHumansRNA MessengerCaenorhabditis elegansCaenorhabditis elegans ProteinsMolecular BiologyGene030304 developmental biologyGenome HelminthCell MembraneGenetics and GenomicsRC581-607biology.organism_classificationrespiratory tract diseasesTranscription Factor AP-1Emerging Infectious DiseasesGenesRNAParasitologyGeneric health relevanceRNA HelminthImmunologic diseases. AllergyPLoS Pathogens
researchProduct

Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions.

2013

Contains fulltext : 118153.pdf (Publisher’s version ) (Open Access) Hepatitis C virus (HCV) infected patients often take multiple co-medications to treat adverse events related to HCV therapy, or to manage other co-morbidities. Drug-drug interactions associated with this polypharmacy are relatively new to the field of HCV pharmacotherapy. With the advent of the direct-acting antivirals telaprevir and boceprevir, which are both substrates and inhibitors of the cytochrome P450 (CYP) 3A iso-enzyme, knowledge and awareness of drug-drug interactions have become a cornerstone in the evaluation of patients starting and continuing HCV combination therapy. In our opinion, an overview of conducted dr…

medicine.medical_specialtyCombination therapyPharmacologyAntiviral AgentsDrug interactionsTelaprevirTelaprevirchemistry.chemical_compoundPharmacotherapyAnti-Infective AgentsBoceprevirOpiate Substitution TreatmentmedicineHumansHypnotics and SedativesHypoglycemic AgentsPharmacokineticsSummary of Product CharacteristicsIntensive care medicineAdverse effectPolypharmacyBoceprevirHepatologybusiness.industryHCV therapyCardiovascular AgentsHepatitis C ChronicAntidepressive AgentsBuprenorphinechemistryCardiovascular agentHepatitis C virus infectionDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsPoverty-related infectious diseases Infectious diseases and international health [N4i 3]businessImmunosuppressive AgentsMethadonemedicine.drug
researchProduct